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and promote services and/or treatments. This study can also help to assess the cost-
beneﬁt ratio of folic acid supplementation and the cost-beneﬁt ratio of recommended 
food supplements.
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OBJECTIVES: Fibromyalgia or ﬁbromyalgia syndrome (FMS) is characterized by 
chronic widespread muscular pain and generalized tender points, often accompanied 
by a number of associated symptoms such as fatigue, sleep disturbance, psychological 
distress. The objective of this study was to assess the medical resource utilization 
(MRU) and workdays lost (WDL) of FMS patients according to the level of pain and 
fatigue. METHODS: The Adelphi Fibromyalgia Disease Speciﬁc Programme is a cross-
sectional survey among 2159 FMS patients in France, Germany, Italy, Spain and the 
UK. The survey included one questionnaire ﬁlled in by the patient and one by the 
physician. Patient health states were deﬁned on the basis of items 15 and 16 (100 mm 
VAS scales) of FIQ (Fibromyalgia Impact Questionnaire). RESULTS: From the pool 
of 2159 FMS patients, most patients with moderate pain (80.5%) or severe pain 
(95.5%) also suffered from fatigue. A total of 1341 patients had signiﬁcant fatigue 
(cut off: 50 mm), associated with mild (40 mm; N  154), moderate (40–70 mm; N 
 587) or severe (70 mm; N  600) pain. The annual number of physician visits per 
patient (5.71, 6.14 and 7.47 respectively), co-medication costs per 4 weeks (£3.66, 
£5.48 and £8.11), as well as the annual hospitalisation rate (2.6%, 5.6% and 7.5%) 
and length of stay per patient per year (0.42, 1.69 and 1.95 days, respectively) 
increased following the level of pain. Similarly, the percentage of patients on sick leave 
and its duration were larger in patients with fatigue and moderate (11.9% and 40 
weeks) or severe (20.0% and 44 weeks) pain, compared to patients with mild pain 
(8.4% and 33 weeks). CONCLUSIONS: In patients with FMS who present with sig-
niﬁcant fatigue, medical resource utilization and workdays lost are driven by the level 
of pain.
PMS26
HEALTH CARE RESOURCES AND COSTS OF FIBROMYALGIA:  
A REVIEW OF THE EVIDENCE
Desjardins B1, Berbari J1, Farah B2, Azzabi-Zouraq I3, Iskedjian M2
1PharmIdeas Research and Consulting Inc., Ottawa, ON, Canada, 2PharmIdeas Research and 
Consulting Inc, Oakville, ON, Canada, 3PharmIdeas Research and Consulting Inc., Lyon, 
France
OBJECTIVES: This review was performed to document and analyse the evolution of 
costs in Fibromyalgia (FM). METHODS: A systematic review (SR) was performed 
using Mesh terms (Medline 1980–2009). Articles on FM were selected if they pre-
sented direct or indirect costs. Two researchers extracted costs which were divided by 
type of resource. Total direct costs were divided by health care visits, hospitalization, 
procedures and drug costs; and, indirect costs in two types: absenteeism or work with 
reduced productivity. Costs were compared and differences were documented. Trends 
analysis was performed after converting results to USD$. RESULTS: Out of 28 cita-
tions, 7 articles were included. Four papers reported costs in USD$, 2 in Euros and 1 
in CA$. Costs were reported /patient/year, except for the Canadian 6-month study. 
All studies identiﬁed total direct costs, disaggregated in subtypes by 6 of them. Five 
studies reported total indirect costs; 3/5 reported on absenteeism and on reduced 
productivity. Three US studies were performed before 2000, and one in 2005. There 
was a progression in total direct costs/patient/yr from 1996 to 2005 from USD$2274 
to USD$7286 respectively and for total indirect costs, from USD$1010 to USD$2913. 
Two European analyses provided similar total direct costs/patient/yr, but did not 
report on the same indirect costs. The 6-month results were excluded from the primary 
trend analysis. A slope of y  1990x and R2  0.83 was obtained, showing a reliable 
increasing trend. Including the 6-month analysis (multiplied by 2), results changed to 
y  1881x, R2  0.64. CONCLUSIONS: This SR and trend analysis documented two 
major categories and subtypes of costs reported for FM, and detected an increasing 
trend. Limitations arose from adjusting indirect costs in two studies and the inclusion 
of papers from various settings. Further detailed analyses, including costs of comor-
bidities and premature death, are warranted to establish the full economic impact of 
FM.
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OBJECTIVES: The purpose of this analysis was to assess the direct and indirect costs 
of rheumatoid arthritis (RA) treatment in Poland in the years 2003–2007. METHODS: 
In order to estimate the direct medical costs of RA, including the costs of medical 
consultation, hospitalization, rehabilitation, drugs and diagnostic tests, data for the 
years 2004–2007 of the National Health Fund were used. Indirect costs like costs of 
pensions for incapacity for work, the costs of rehabilitation and social costs of rents 
for the years 2003–2007 were obtained from the Department of Social Security. 
RESULTS: Direct medical costs of RA in Poland ranged from 115.7 million pln in 
2004 to 126.5 million pln in 2007. Costs of hospital treatment amounted up to 70% 
of the direct costs in 2007. Indirect costs amounted to almost 60 million pln in 2003 
and rose to over 62 million pln in 2007. The largest share of these costs constitute 
the costs of pensions for incapacity for work, which share in indirect costs was 83% 
in 2007. Costs of rehabilitation were increasing in subsequent years (from around 4 
million in 2003 to 9.7 million pln in 2007). The total cost of treatment of RA showed 
an upward trend, reaching a value almost 177 million pln in 2004 and increased to 
almost 188 million pln in 2007. The total cost was dominated by the direct costs with 
share equal to 65% in 2004 to 66.8% in 2007 of the total costs. CONCLUSIONS: 
From year to year RA causes a growing economic burden on the health care and social 
insurance in Poland. The cost structure is dominated by the direct costs, which in turn 
largely consist of the costs of hospital treatment. Indirect costs are affected largely by 
rents due to the inability to work.
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OBJECTIVES: To estimate the costs savings in outpatient medical resource use associ-
ated with diagnosing ﬁbromyalgia during the four years after diagnosis in ﬁve European 
countries (UK, France, Italy, Spain, Germany). METHODS: The UK resource use data 
were extracted from medical records of 2,260 patients diagnosed with FM between 
1998 and 2003 in the General Practice Research Database (GPRD). For the others 
countries, a questionnaire was created based on the UK data and local experts, GP 
and rheumatologists, were asked to compare their own clinical practice to UK prescrip-
tions in terms of tests, drugs, general practitioners and specialists visits, over a period 
of 4 years before diagnosis to 4 years after the diagnosis. Medical resource use if 
diagnosis would not have been established was predicted using adapted published 
Poisson loglinear regression models. The observed and predicted trends in outpatient 
resource use and costs were calculated, so the impact of diagnosis could be evaluated 
for each of these medical resources. RESULTS: In the ﬁve countries studied, whereas 
costs are increasing during the years till diagnosis (40–72% in 4 years, a394a per 
patient the year of diagnosis from the health care perspective in Italy to a2108 in 
Germany), after diagnosis a decrease is observed (5–10%). Compared to a diagnosed 
FM patient, a non-diagnosed patient represents an incremental cost that ranges 
between 97a (Italy) and a421a (Spain) per patient and per year from the health care 
payer perspective. These higher costs are due to more GP and specialist visits and 
diagnostic tests. An earlier diagnosis allows from the societal perspective savings ranged 
from 106a (Italy) to a432 (Spain) per patient and per year. CONCLUSIONS: Making 
the diagnosis of FM reduces costs gradually independent of the country studied.
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OBJECTIVES: To compare the resource use and related costs associated with the 
management of ﬁbromyalgia (FM) in ﬁve European countries (UK, France, Italy, 
Spain, Germany). METHODS: The UK resource use data were extracted from medical 
records of 2,260 patients diagnosed with FM between 1998 and 2003 in the General 
Practice Research Database (GPRD). For the other countries, a questionnaire was 
created based on the UK data and local experts, GP and rheumatologists, were asked 
to compare their own clinical practice to UK prescriptions in terms of tests, drugs, 
general practitioners and specialists visits, over a period of 4 years before diagnosis 
to 4 years after the diagnosis. Information on paramedical and alternative care was 
also collected for France, Italy, Spain, Germany. Inpatient care and productivity loss 
were not included in GPRD and thus also not in the questionnaire. The public payer 
and societal perspective were used. RESULTS: Resource use and average costs related 
to lab tests per person-year from the public health care payer perspective were highest 
in Spain (101a) and the UK, the year of diagnosis and decrease afterwards (a69 in 
Spain). Drug costs are higher in Germany (a242a) mainly due to the higher unit costs. 
Costs related to GP visits increase till diagnosis in Germany (a892) and the UK. The 
costs for referrals to specialists are the highest before diagnosis in the UK (a131), 
France, and Italy. Overall, the highest mean annual total cost per patient from the 
societal perspective was found in Germany (a1,897), the lowest in Italy (a454). The 
highest patient contribution was seen in France (54%), the lowest in Italy (16%). 
CONCLUSIONS: Although moderate differences between countries were found in the 
management of FM, once a formal FM diagnosis was made, the resource use and costs 
decreased independent of the countries studied.
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OBJECTIVES: Balloon kyphoplasty (BKP) is a minimally invasive procedure for the 
treatment of painful vertebral compression fractures (VCFs). Superior clinical out-
comes data versus non surgical management (NSM) has recently been demonstrated 
in a large RCT comparing BKP and VCF. Furthermore, preliminary results of a large 
